Nicholas Ashton

Differences between Alzheimer’s disease biomarkers: p-Tau181, p-Tau231 & p-Tau217

Biomarkers for Alzheimer’s disease in a preclinical setting

The accuracy of plasma biomarkers for Alzheimer’s disease outside of a controlled setting

Plasma biomarkers for Alzheimer’s disease as pre-screening tools

Bringing plasma biomarkers into clinical practice: what does the future hold?

Beyond Aβ and p-Tau: novel biomarkers under investigation for Alzheimer’s disease

The ability of plasma P-tau231 to detect preclinical Alzheimer’s disease

Investigating novel plasma-based P-tau biomarkers